Aktienanalyse zu AnaptysBio, Inc. (ANAB)ANABAnaptysBio, Inc.

AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AnaptysBio is currently not a strong buy due to its current price of $46.61 being below the recent analyst price targets, which range from $60 to $90. The RSI is at 42.212, indicating it is nearing oversold territory, but the recent earnings report showed a significant net income of $183.88 million driven by a tax benefit, suggesting potential for recovery. However, the risk remains high with a forward P/E of 21.0084, indicating that the stock may be overvalued based on future earnings expectations, especially considering the volatility in its earnings and the recent litigation outcomes.

8 analysts cover ANAB: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 74.13.